Akili, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 0.749 million compared to USD 0.111 million a year ago. Net loss was USD 11.15 million compared to USD 16.82 million a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.435 USD | -0.23% | +2.14% | -10.70% |
06-18 | Akili's EndeavorOTC Gets FDA Clearance For ADHD Treatment | MT |
06-18 | Akili Gets FDA Clearance for ADHD Video Game Over-the-Counter Treatment | DJ |
1st Jan change | Capi. | |
---|---|---|
-10.70% | 34.25M | |
+4.03% | 210B | |
+7.91% | 186B | |
+31.91% | 158B | |
+33.23% | 113B | |
+2.28% | 66.13B | |
+21.03% | 56.25B | |
+0.11% | 49B | |
-6.88% | 38.16B | |
+0.85% | 35.98B |
- Stock Market
- Equities
- AKLI Stock
- News Akili, Inc.
- Akili, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023